Advertisement

Topics

Christmas Comes Early For KURA, ANTH On Track, ABBV Hits All-time High

02:46 EDT 8 Sep 2017 | RTTNews

Today's Daily Dose brings you news about Amgen's chronic migraine study; Ampio's non compliance with certain listing standards of NYSE; Kura's phase II trial of Tipifarnib; Adamas' phase Ib epilepsy trial and AbbVie's phase IIb dose-ranging study of Upadacitinib in atopic dermatitis.

Original Article: Christmas Comes Early For KURA, ANTH On Track, ABBV Hits All-time High

NEXT ARTICLE

More From BioPortfolio on "Christmas Comes Early For KURA, ANTH On Track, ABBV Hits All-time High"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...